Download this eBook to take a closer look at past efforts, modern challenges, and future advances!

Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 

There’s a new cell-based cancer immunotherapy on the block.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.

The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.

We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.

Scientists show the approach can kill cells that cause hardening of heart tissue in mice.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.